image credit: Freepik

Mass spectrometry for gene therapy vector analysis

Researchers show combining mass spectrometry and a gas-phase electrophoretic mobility molecular analyser improves detection of full and empty virus-like particles for gene therapies.

Adeno-associated viruses (AAV) are the leading virus-like particle (VLP) vehicles for gene therapies, but how can AAVs either lacking or carrying an engineered genome be identified?

Native mass spectrometry (MS) is known for its ability to gather highly accurate molecular weights without changing the native biological conformation of analytes, but according to experts, once applied to larger biologics (megadalton species), MS becomes challenging and requires customised instruments.

Read More on European Pharmaceutical Review